Methods of treating cancer using PRMT5 inhibitors

US11571437B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Hillary Quinn · Philadelphia, US
• Kathryn Packman · Newton, US
• Nahor Haddish-Berhane · Doylestown, US
• Geert S.J. Mannens · Lier, BE
• Junguo Zhou · Flemington, US
• Anthony T. Greway · Bound Brook, US
• Dirk Brehmer · Glückstadt, DE
• Yue Guo · North Wales, US
• Tongfei Wu · Leuven, BE
• Hong Xie · Dresher, US
• Josh Lauring · Towson, US

Key dates

• Filing date: Jun 5, 2020
• Grant date: Feb 7, 2023
• Expiry date: Jun 5, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.